Multidisciplinary Treatment of Advanced Cancer of the Esophagus and Gastroesophageal Junction: A European Center's Approach

Surgical Oncology Clinics of North America

Volumn 17, Issue 3, 2008, Pages 485-502

  Lerut, Toni ^a   Moons, Johnny ^a   Coosemans, Willy ^a   Decaluwé, Herbert ^a   Decker, Georges ^a   De Leyn, Paul ^a   Nafteux, Philippe ^a   Van Raemdonck, Dirk ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADVANCED CANCER; BARRETT ESOPHAGUS; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DYSPHAGIA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; GEOGRAPHIC DISTRIBUTION; HUMAN; LOWER ESOPHAGUS SPHINCTER; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MONOTHERAPY; PREOPERATIVE RADIOTHERAPY; REVIEW; WEIGHT REDUCTION;

ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; EUROPE; HUMANS; NEOADJUVANT THERAPY; PATIENT CARE TEAM; STOMACH NEOPLASMS;

EID: 43449116356     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2008.02.007     Document Type: Review

References (79)

1. Devesa S.S., Blot W.J., and Fraumen Jr. J.F. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83 10 (1998) 2049-2053
2. Ward E.M., Thun M.J., Hannan L.M., et al. Interpreting cancer trends. Ann N Y Acad Sci 1076 (2006) 29-53
3. Parkin D.M., Pisarie P., and Ferlay J. Global cancer statistics. CA Cancer J Clin 49 1 (1999) 33-64
4. Pera M., Manterola C., Vidal O., et al. Epidemiology of esophageal adenocarcinoma. J Surg Oncol 92 3 (2005) 151-159
5. Bossetti C., Levi F., Ferlay J., et al. Trends in oesophageal cancer incidence and mortality in Europe. Int J Cancer 122 (2007) 1118-1129
6. Watt E., and Whyte F. The experience of dysphagia and its effect on the quality of life of patients with oesophageal cancer. Eur J Cancer Care (Engl) 12 2 (2003) 183-193
7. Akiyama H., Tsurumaru M., Udagawa H., et al. Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg 220 3 (1994) 364-372
8. Nishimaki T., Suzuki T., Kanda T., et al. Extended radical esophagectomy for superficially invasive carcinoma of the esophagus. Surgery 125 2 (1999) 142-147
9. Vaughan T.L., Davis S., Kristal A., et al. Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 4 2 (1995) 85-92
10. Chow W.H., Blot W.J., Vaughan T.L., et al. Body mass index and risk of adenocarcinoma of the esophagus and gastric cardia. J Natl Cancer Inst 90 2 (1998) 150-155
11. Earlam R., and Cunha-Melo J.R. Oesophageal squamous cell carcinoma: I. A critical review of surgery. Br J Surg 67 6 (1980) 381-390
12. Müller J.M., Erasmi H., Stelzner M., et al. Surgical therapy of esophageal carcinoma. Br J Surg 77 8 (1990) 845-857
13. Jamieson G.G., Mathew G., Ludemann R., et al. Postoperative mortality following esophagectomy and problems in reporting its rate. Br J Surg 91 8 (2004) 943-947
14. van Lanschot J.J., Hulscher J.B., Buskens C.J., et al. Hospital volume and hospital mortality for esophagectomy. Cancer 91 8 (2001) 1574-1578
15. Dimick J.B., Goodney P.P., Orringer M.B., et al. Specialty training and mortality after esophageal cancer resection. Ann Thorac Surg 80 1 (2005) 282-286
16. Birkmeyer J.D., Dimick J.B., and Staiger D.O. Operative mortality and procedure volume as predictors of subsequent hospital performance. Ann Surg 243 3 (2006) 411-417
17. Christian C.K., Gustafson M.L., Betensky R.A., et al. The Leapfrog volume criteria may fall short in identifying high-quality surgical centres. Ann Surg 238 4 (2003) 447-455 [discussion: 455-7]
18. Metzger R., Bollschweiler E., Vallböhmer D., et al. High volume centres for esophagectomy: what is the number needed to achieve low postoperative mortality?. Dis Esophagus 17 4 (2004) 310-314
19. Killeen S.D., O'Sullivan M.J., Coffey J.C., et al. Provider volume and outcomes for oncological procedures. Br J Surg 92 4 (2005) 389-402
20. Orringer M.B., Marshall B., and Iannettoni M.D. Transhiatal esophagectomy: clinical experience and refinements. Ann Surg 230 3 (1999) 392-400
21. Luketich J.D., Alvelo-Rivera M., Buenaventura P.O., et al. Minimally invasive esophagectomy: outcomes in 222 patients. Ann Surg 238 4 (2003) 486-494
22. Skinner D.B. En bloc resection for neoplasms of the esophagus and cardia. J Thorac Cardiovasc Surg 85 1 (1983) 59-71
23. Fumagalli U., and Panel of experts. Resective surgery for cancer of the thoracic esophagus. Results of a consensus conference held at the VIth World Congress of the International Society for Diseases of the Esophagus. Dis Esophagus 9 (1996) 30-38
24. Fujita H., Sueyoshi S., Tanaka T., et al. Optimal lymphadenectomy for squamous cell carcinoma in the thoracic esophagus: comparing the short and long-term outcome among the four types of lymphadenectomy. World J Surg 27 5 (2003) 571-579
25. Lagarde S., ten Kate F., Reitsma J., et al. Prognostic factors in adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol 24 (2006) 4347-4355
26. Lerut T., Coosemans W., Decker G., et al. Leuven Collaborative Workgroup for Esophageal Carcinoma. Extracapsular lymph node involvement is a negative prognostic factor in T3 adenocarcinoma of the distal esophagus and gastroesophageal junction. J Thorac Cardiovasc Surg 126 4 (2003) 1121-1128
27. Matsubara T., Ueda M., Yanagida O., et al. How extensive should lymph node dissection be for cancer of the thoracic esophagus?. J Thorac Cardiovasc Surg 107 4 (1994) 1073-1078
28. Altorki N., and Skinner D. Should en bloc esophagectomy be the standard of care for esophageal carcinoma?. Ann Surg 234 5 (2001) 581-587
29. Hagen J.A., DeMeester S.R., Peters J.H., et al. Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Ann Surg 234 4 (2001) 520-530
30. Collard J.M., Otte J.B., Fiasse R., et al. Skeletonizing en bloc esophagectomy for cancer. Ann Surg 234 1 (2001) 25-32
31. Swanson S.J., Batirel H.F., Bueno R., et al. Transthoracic esophagectomy with radical mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy for esophageal carcinoma. Ann Thorac Surg 72 6 (2001) 1918-1924
32. Lerut T., Nafteux P., Moons J., et al. Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma. Ann Surg 240 6 (2004) 962-972
33. Hulscher J.B., van Sandick J.W., Tijssen J.G., et al. The recurrence pattern of esophageal carcinoma after transhiatal resection. J Am Coll Surg 191 2 (2000) 143-148
34. Becker C.D., Barbier P.A., Terrier F., et al. Patterns of recurrence of esophageal carcinoma after transhiatal esophagectomy and gastric interposition. AJR Am J Roentgenol 148 2 (1987) 273-277
35. Gignoux M., Roussel A., Paillot B., et al. The value of preoperative radiotherapy in esophageal cancer: Results of a study of the E.O.R.T.C. World J Surg 11 4 (2005) 426-432
36. Nygaard K., Hagen S., Hansen H.S., et al. Preoperative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of preoperative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg 16 6 (1992) 1104-1109
37. Hulscher J.B., van Sandick J.W., de Boer A.G., et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 347 21 (2002) 1662-1669
38. Hulscher J.B., and van Lanschot J.J. Individualised surgical treatment of patients with an adenocarcinoma of the distal esophagus or gastro-esophageal junction. Dig Surg 22 3 (2005) 130-134 [epub 2005 May 16]
39. Ando N., Ozawa S., Kitagawa Y., et al. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg 232 2 (2000) 225-232
40. Isono K., Sato H., and Nakayama K. Results of a nationwide study on the three-field lymph node dissection of esophageal cancer. Oncology 48 5 (1991) 411-420
41. Roder J.D., Busch R., Stein H.J., et al. Ratio of invaded to removed lymph nodes as a predictor of survival in squamous cell carcinoma of the oesophagus. Br J Surg 81 3 (1994) 410-413
42. Baba M., Aikou T., Yoshinaka H., et al. Long-term results of subtotal esophagectomy with three-field lymphadenectomy for carcinoma of the thoracic esophagus. Ann Surg 219 (1994) 310-316
43. Killinger W.A., Rice T.W., Adelstein D.J., et al. Stage II esophageal carcinoma: the significance of T and N. J Thorac Cardiovasc Surg 111 5 (1996) 935-940
44. Arnott S.J., Duncan W., Gignoux M., et al. Oesophageal cancer collaborative group. Preoperative radiotherapy for esophageal carcinoma. Cochrane Database Syst Rev 19 4 (2005) CD001799
45. Roth J., Pass H., Flanagan M., et al. Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus. J Thorac Cardiovasc Surg 96 (1998) 242-248
46. Schlag P. Randomized trial of preoperative chemotherapy for squamous cell carcinoma of the esophagus. Arch Surg 127 (1992) 1446-1450
47. Maipang T., Vasinnanukorn P., Petpichetchian C., et al. Induction chemotherapy in the treatment of patients with carcinoma of the esophagus. J Surg Oncol 56 (1994) 191-197
48. Law S., Fok M., Chow S., et al. Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg 114 (1997) 210-217
49. Kelsen D., Ginsberg R., Pajak T., et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 339 (1998) 1979-1984
50. Ancona E., Ruol A., Santi S., et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma. Cancer 91 (2001) 2165-2174
51. Medical research council Oesophageal cancer working group. Surgical resection with or without preoperative chemotherapy in esophageal cancer: a randomised controlled trial. Lancet 359 (2002) 1727-1734
52. Malthaner R., Wong R., Rumble R., et al. Neoadjuvant or adjuvant therapy for respectable esophageal cancer: a systematic review and meta-analysis. BMC Med 2 (2004) 35
53. Gebski V., Burmeister B., SMithers B.M., et al., Australian Gastro-Intestinal Trials Group. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 8 3 (2007) 226-234
54. Le Prise E., Etienne P., Meunier B., et al. A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 73 (1994) 1779-1784
55. Apinop C., Puttisak P., and Preecha N. A prospective study of combined therapy in esophageal cancer. Hepatogastroenterology 41 (1994) 391-393
56. Walsh T., Noonan N., Hollywood D., et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335 (1996) 462-467
57. Bosset J., Gignoux M., Triboulet J., et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous cell cancer of the esophagus. N Engl J Med 337 (1997) 161-167
58. Urba S., Orringer M., Turrisi A., et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19 (2001) 305-313
59. Burmeister B., SMithers M., Gebski V., et al. A randomized phase III study comparing surgery alone with chemoradiation therapy followed by surgery for resectable carcinoma of the esophagus: an intergroup study of the Trans-Tasman Radiation Oncology Group (TROG) and the Australian Gastro-Intestinal Trials Group (AGITG). Lancet Oncol 6 (2005) 659-668
60. Lee J.L., Park S.I., Kim S.B., et al. A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for respectable esophageal squamous cell carcinoma. Ann Oncol 15 6 (2004) 947-954
61. Walsh T. The role of multimodality therapy in improving survival: a prospective randomised trial. In: Predicting, defining and improving outcomes for esophageal carcinoma [MD thesis]. Dublin: Trinity College, University of Dublin; 1995. p. 124-50.
62. Tepper J., Krasna M., Niedzwiecki D., et al. Superiority of trimodality therapy to surgery alone in esophageal cancer: results of CALGB 9781. J Clin Oncol 24 Suppl 18S (2006) 4012 [abstract]
63. Carstens H., Albertsson M., Friesland S., et al. A randomized trial of chemoradiotherapy versus surgery alone in patients with resectable esophageal cancer. J Clin Oncol 25 18S (2007) 4530
64. Geh J.I., Bond S.J., Bentzen S.M., et al. Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response. Radiother Oncol 78 3 (2006) 236-244 [epub 2006 Mar 20]
65. Urschel J., and Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 185 (2003) 538-543
66. Greer S., Goodney P., Sutton J., et al. Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis. Surgery 137 (2005) 172-177
67. Fiorica F., Di Bona D., Schepis F., et al. Preoperative chemoradiotherapy for esophageal cancer: a systematic review and meta-analysis. Gut 53 (2004) 925-930
68. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 17 1 (1996) 1-12
69. Egger M., Ebrahim S., and Smith G.D. Where now for meta-analysis?. Int J Epidemiol 31 (2002) 1-5
70. Hagry O., Coosemans W., De Leyn P., et al. Effect of preoperative chemoradiotherapy on postsurgical morbidity and mortality in cT3-4+/-cM1lymph cancer of the oesophagus and gastroesophageal junction. Eur J Cardiothorac Surg 24 2 (2003) 179-186
71. Flamen P., Van Cutsem E., Lerut A., et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 13 3 (2002) 361-368
72. Lordick F., Ott K., Krause B.J., et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 8 9 (2007) 797-805
73. Kim L.K., Ryu J.S., Kim S.B., et al. Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy. Eur J Cancer 43 9 (2007) 1385-1391
74. Choi J.Y., Jang H.J., Shim Y.M., et al. 18F-FDG PET in patients with esophageal squamous cell carcinoma undergoing curative surgery: prognostic implications. J Nucl Med 45 11 (2004) 1843-1850
75. Bédard E.L., Inculet R.I., Malthaner R.A., et al. The role of surgery and postoperative chemoradiation therapy in patients with lymph node positive esophageal carcinoma. Cancer 91 12 (2001) 2423-2430
76. Cooper J.S., Guo M.D., Herskovic A., et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 281 17 (1999) 1623-1627
77. Bedenne L., Michel P., Bouché O., et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 25 10 (2007) 1160-1168
78. Piessen G., Briez N., Triboulet J.P., et al. Patients with locally advanced esophageal carcinoma non responder to radiochemotherapy: who will benefit from surgery?. Ann Surg Oncol 14 7 (2007) 2036-2044
79. Stahl M., Stuschke M., Lehmann N., et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23 10 (2005) 2310-2317